<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55492">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02123732</url>
  </required_header>
  <id_info>
    <org_study_id>DbXell1234</org_study_id>
    <nct_id>NCT02123732</nct_id>
  </id_info>
  <brief_title>Role of DbXell in the Treatment of Subjects With Mildly Uncontrolled Type 2 Diabetes Mellitus</brief_title>
  <official_title>Role of DbXell in the Treatment of Subjects With Mildly Uncontrolled Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laniado Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>K.G.S Research &amp; Entrepreneurship, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laniado Hospital</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-arm, single-blind, crossover, placebo-controlled clinical study, with 24 weeks
      of therapy to evaluate the efficacy and safety of DbXell  in improving metabolic control in
      patients with Type 2 Diabetes that is mildly uncontrolled, defined as HbA1c above target but
      less than 8.0% on their current conventional therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in HbA1C concentrations and fasting glucose levels</measure>
    <time_frame>6 months from last patient in</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DbXell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: DbXell three times daily for 12 weeks and then switching to Placebo of DbXell  for 12 additional months Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo of DbXell Placebo of DbXell  three times daily for 12 weeks and then switching to DbXell  for 12 additional weeks Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DbXell</intervention_name>
    <arm_group_label>DbXell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects with age of 18-70 years Established type 2 diabetes mellitus
             as defined by the American Diabetes Association, but of duration less than 10 years.

          -  Suboptimal glycemic control as judged by HbA1c over target but not more than
             8.0%.Current medication of not more than 2 oral hypoglycemic agents. No current or
             past insulin or GLP1 therapy.

          -  FPG ≤ 180 mg/dL

          -  Hemoglobin level of ≥ 10.0 g/dL

          -  Serum ALT ≤ 2.5 times upper limit of normal

          -  Serum creatinine &lt; 1.5 times upper limit of normal

        Exclusion Criteria:

          -  Female of childbearing potential

          -  Subjects with symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or other symptomatic ischemic arterial diseases necessitating medical
             treatment

          -  Uncontrolled hypertension (SBP &gt; 160 mmHg and/or DBP &gt; 100 mmHg)

          -  History of renal and/or liver disease

          -  History of or the presence of any clinical evidence of malignancies

          -  Presence of exacerbation of chronic illnesses, severe and acute infections,
             complicated infections

          -  Current treatment with systemic corticosteroids or herbal (alternative) medicines

          -  Participation in any other intervention trial within 30 days prior to Screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J Niven, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laniado Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laniado Hospital, Diabetes Unit</name>
      <address>
        <city>Netanya</city>
        <zip>42150</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark J Niven, MD</last_name>
      <phone>+972-9-860-9325</phone>
      <email>mniven@laniado.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Odelia Shmulevitz, Mrs.</last_name>
      <phone>+972-9-892-5248</phone>
      <email>oshmulevitz@laniado.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Mark J Niven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laniado Hospital</investigator_affiliation>
    <investigator_full_name>Laniado Hospital</investigator_full_name>
    <investigator_title>Dr Mark J NIVEN Director of Endocrine and Diabetes Unit</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Herbal</keyword>
  <keyword>food supplement</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
